**Skye Bioscience is a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet needs**

## Market Information

**OTCQB : SKYE**

**Market Cap:** $12.3M[1]

**Shares OS**: 495.9M[2]

**Options + Warrants:** 173.9M[2]

[1]22/11/08
[2]22/06/30

## Recent Advances

**22/09/30:** Stockholders vote in favor of arrangement agreement with Emerald Health Therapeutics

**22/09/20:** Completes drug production for Phase 1 clinical study

**22/09/01:** Files definitive proxy statement and announces stockholders meeting date

**22/08/19:** Reports that Emerald Health Therapeutics shareholders voted in favor of plan of arrangement with Skye

**22/07/21:** Selects NextPharma as Phase 2 contract drug manufacturer

**22/07/20:** Updates Phase 1 timeline

# Unlocking the pharmaceutical potential of cannabinoids

## Investment Highlights

### Exploiting the Endocannabinoid System

The endocannabinoid system's (ECS) role in modulating body functions makes it a promising target for cannabinoids and small molecules able to provide therapeutic benefit while meeting modern medical standards. Recent clinical studies proved a particular cannabinoid's ability to control epileptic seizures. This was just one result justifying discovery efforts to enhance and validate mechanisms to affect the ECS; improve the delivery and bioavailability of promising molecules; establish intellectual property; and advance novel compounds through development. This is Skye's focus and forte.

### Large Market, Unmet Needs

The eye is rich with cannabinoid receptors that can be targeted to affect multiple conditions in that organ. A key eye disease, glaucoma, afflicts ~80M (American Academy of Ophthamology) people worldwide and is a $7B pharmaceutical drug market. Current drugs that reduce eye pressure cannot consistently prevent glaucoma progression to vision loss. Notably, human studies have shown THC's ability to positively affect a key risk factor of glaucoma – but THC in its natural form is not a clinically viable therapeutic. Skye got an early start on creating an enhanced cannabinoid derivative to address this untapped opportunity and establishing patent protection.

### Novel Drugs

Designed to provide distinct capabilities compared to currently approved glaucoma drugs, Skye's SBI-100 is engineered to enhance its local delivery (avoiding systemic side effects) and bioavailability in the eye. In an animal study comparing latanoprost, the glaucoma standard of care, SBI-100 Ophthalmic Emulsion ("OE"), which targets the CB1 receptor, was superior in lowering intraocular pressure and demonstrated superior duration of response. In Q4 2022, Skye expects to start enrolling subjects in a Phase 1 study and file an IND with the FDA to start Phase 2 in 2023 to assess the utility and safety of SBI-100 Ophthalmic Emulsion.

### Creating a New Class of Pharmaceutical Therapeutics

The recent success of a pharmaceutical development company in realizing the therapeutic and commercial value of a cannabinoid for a notable disease, epilepsy, led to its $7.2B acquisition. Applying modern science and rigorous clinical and regulatory review, Skye is developing proprietary synthetic cannabinoid derivatives and small molecules that represent new classes of medicine to benefit both patients and shareholders.

## Product Pipeline




## Positioned for Value Creation

### Completed Steps

- GLP toxicology study for SBI-100 OE
- Head-to-head study in rabbits of SBI-100 OE effect on IOP versus netarsudil and latanoprost alone and in combination to evaluate potential additive and/or synergistic effects of SBI-100 OE
- CMC & GLP manufacturing of SBI-100 OE
- Genotoxicity studies to assess potential for induction of genetic mutations or chromosomal damage
- Repeated dose toxicology study in multiple species to satisfy FDA's IND requirement
- Met Australian Human Ethics Research Committee requirements to begin Phase 1

### Upcoming Milestones

- Close acquisition of Emerald Health Therapeutics in Q4 to extend operating runway
- Begin subject enrollment for Phase 1 study of SBI-100 OE in Q4 2022
- Submit Investigational New Drug Application for Phase 2 study of SBI 100 OE in Q4 2022
- Finalize assessment of development potential of SBI-200
- Phase 1 data for SBI-100 OE in Q2 2023

## Cannabinoid Pharmaceutical Innovation Program

### Vivacell Biotechnology España

Vivacell is a global pioneer in the discovery and development of novel cannabinoid derivatives for the treatment of serious disease.

Under an exclusive sponsored research agreement, Vivacell has developed a proprietary screening platform which has screened over 75 molecules to analyze key molecular targets in a range of disease pathways initially focused on ophthalmology.

### University of Mississippi

Drawing on 50 years of intellectual capital in cannabinoid chemistry and physiology from the first entity with a federal license to cultivate cannabis for research purposes.

Skye secured from Ole Miss "all fields" licenses for SBI-100 molecule and SBI-200, permitting development for any therapeutic indication by any route of administration for any human and veterinary indication.

## Our Team

### Management

**Punit Dhillon**
Chief Executive Officer and Executive Chairman

**Kaitlyn Arsenault, CPA**
Chief Financial Officer

**Tu Diep, MSc**
Chief Development Officer

### Board of Directors

**Punit Dhillon**
Chief Executive Officer and Executive Chairman

**Margaret Dalesandro,** PhD
Board Director, OncSec Medical

**Praveen Tyle,** PhD
President & CEO, Invectys, Inc

**Keith W. Ward,** PhD
President & CEO, InterveXion Therapeutics

### Scientific Advisory Board

**Eduardo Munoz,** MD, PhD
Professor of Immunology, University of Córdoba

**Giovanni Appendino,** PhD
Professor of Chemistry, University of Eastern Piedmont

### Clinical Advisory Board

**Jeffery Goldberg,** MD, PhD
Professor & Chair of Ophthalmology, Stanford University

**Louis Pasquale,** MD
Professor of Ophthalmology, Mt. Sinai School of Medicine

**Robert Ritch,** MD
Professor of Ophthalmology, Mt. Sinai School of Medicine

**Miguel González-Andrades,** MD, PhD
Clinician Scientist of Ophthalmology, Reina Sofia University Hospital